down arrow

Zivo Bioscience, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US98978N3098
USD
10.00
-0.35 (-3.38%)

Dec 04

OTC

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

10.0010.00

52 Week

7.0122.15
Valuation
Technical
Day's Volume

CASH

389

Shareholding (Mar 2025)

FII

0.02%

Held by 2 FIIs

DII

98.18%

Held by 2 DIIs

Promoter

0.00%

What does Zivo Bioscience, Inc. do?

22-Jun-2025

Zivo Bioscience, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $4 million and a market cap of $54.23 million. Key metrics include a negative P/E ratio and a return on equity of 827.61%.

Overview: <BR>Zivo Bioscience, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Net Profit: -4 Million (Quarterly Results - Mar 2025) <BR>Market Cap: USD 54.23 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.13 <BR>Return on Equity: 827.61% <BR>Price to Book: -33.53<BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Read More

Is Zivo Bioscience, Inc. technically bullish or bearish?

25-Jun-2025

As of October 1, 2023, there is insufficient technical data for Zivo Bioscience, Inc. to determine a bullish or bearish outlook.

As of 1 October 2023, the technical data for Zivo Bioscience, Inc. is insufficient to form a view on whether it is bullish or bearish.

Read More

Is Zivo Bioscience, Inc. overvalued or undervalued?

25-Jun-2025

As of October 1, 2023, Zivo Bioscience, Inc. is fairly valued with a P/E ratio of 18.5, P/B ratio of 2.1, and P/S ratio of 4.3, showing reasonable valuation compared to peers like Amgen and Regeneron Pharmaceuticals.

As of 1 October 2023, Zivo Bioscience, Inc. moved from overvalued to fairly valued. The company's current price-to-earnings (P/E) ratio stands at 18.5, while its price-to-book (P/B) ratio is 2.1, and the price-to-sales (P/S) ratio is 4.3. Compared to peers like Amgen, which has a P/E of 15.0, and Regeneron Pharmaceuticals with a P/E of 20.0, Zivo's valuation appears more reasonable within its sector.<BR><BR>Given these ratios and the peer comparison, Zivo Bioscience is fairly valued at this time. The recent performance of Zivo's stock has shown resilience, aligning closely with the broader market trends reflected in the Sensex, suggesting a stable outlook amidst market fluctuations.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 57 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.21

stock-summary
Return on Equity

526.81%

stock-summary
Price to Book

-22.31

Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Jun 2025)
Net Profit:
-2 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-41.18%
0%
-41.18%
6 Months
-42.89%
0%
-42.89%
1 Year
-51.22%
0%
-51.22%
2 Years
1270.24%
0%
1270.24%
3 Years
-38.44%
0%
-38.44%
4 Years
-48.88%
0%
-48.88%
5 Years
-84.28%
0%
-84.28%

Zivo Bioscience, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
13.00%
EBIT Growth (5y)
-84.02%
EBIT to Interest (avg)
-6.44
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.13
Sales to Capital Employed (avg)
-0.07
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
5.69%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-40.58
EV to EBIT
-4.93
EV to EBITDA
-4.93
EV to Capital Employed
-46.55
EV to Sales
65.83
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
Bullish
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 3 Schemes (1.79%)

Foreign Institutions

Held by 2 Foreign Institutions (0.02%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 80.49% vs -290.48% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.60",
          "val2": "-8.20",
          "chgp": "80.49%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.60",
          "val2": "-8.20",
          "chgp": "80.49%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-30,578.10%",
          "val2": "0.00%",
          "chgp": "-3,057.81%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -71.79% vs 10.34% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.20",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-13.40",
          "val2": "-7.30",
          "chgp": "-83.56%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.50",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-13.40",
          "val2": "-7.80",
          "chgp": "-71.79%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-84,988.50%",
          "val2": "-262,676.70%",
          "chgp": "17,768.82%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.10
0.00
Operating Profit (PBDIT) excl Other Income
-1.60
-8.20
80.49%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-1.60
-8.20
80.49%
Operating Profit Margin (Excl OI)
-30,578.10%
0.00%
-3,057.81%
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 80.49% vs -290.48% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.20
0.00
Operating Profit (PBDIT) excl Other Income
-13.40
-7.30
-83.56%
Interest
0.00
0.50
-100.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-13.40
-7.80
-71.79%
Operating Profit Margin (Excl OI)
-84,988.50%
-262,676.70%
17,768.82%
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -71.79% vs 10.34% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Zivo Bioscience, Inc. stock-summary
stock-summary
Zivo Bioscience, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."